LYTIX Relative Valuation - Lytix Biopharma AS - Alpha Spread
L

Lytix Biopharma AS
OSE:LYTIX

Watchlist Manager
Lytix Biopharma AS
OSE:LYTIX
Watchlist
Price: 7.54 NOK -1.82% Market Closed
Market Cap: 374.1m NOK
Have any thoughts about
Lytix Biopharma AS?
Write Note

Relative Value

The Relative Value of one LYTIX stock under the Base Case scenario is 0.73 NOK. Compared to the current market price of 7.54 NOK, Lytix Biopharma AS is Overvalued by 90%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LYTIX Relative Value
Base Case
0.73 NOK
Overvaluation 90%
Relative Value
Price
L
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
31
vs Industry
14
Median 3Y
79.6
Median 5Y
76.5
Industry
7.7
Forward
42.9
vs History
vs Industry
Median 3Y
-6.9
Median 5Y
-7.1
Industry
23.9
Forward
-2.8
vs History
vs Industry
Median 3Y
-6.1
Median 5Y
-6.3
Industry
22.2
vs History
vs Industry
Median 3Y
-6
Median 5Y
-6.3
Industry
24
vs History
2
vs Industry
10
Median 3Y
3.3
Median 5Y
3.2
Industry
2.5
vs History
31
vs Industry
13
Median 3Y
63.2
Median 5Y
61.3
Industry
7.4
Forward
37.2
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.5
vs History
vs Industry
Median 3Y
-3.9
Median 5Y
-4.1
Industry
5.1
Forward
-2.6
vs History
vs Industry
Median 3Y
-3.9
Median 5Y
-4.1
Industry
4.7
Forward
-2.6
vs History
vs Industry
Median 3Y
-4.1
Median 5Y
-4.5
Industry
6.6
vs History
vs Industry
Median 3Y
-4.1
Median 5Y
-4.5
Industry
4.7
vs History
53
vs Industry
7
Median 3Y
51.1
Median 5Y
49.7
Industry
4.7

Multiples Across Competitors

LYTIX Competitors Multiples
Lytix Biopharma AS Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
NO
Lytix Biopharma AS
OSE:LYTIX
381m NOK 93.7 -4.3 -3.4 -3.4
US
Abbvie Inc
NYSE:ABBV
341.9B USD 6.2 64.6 15.8 24.1
US
Amgen Inc
NASDAQ:AMGN
180.5B USD 5.8 57.7 20.2 36.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
129B USD 9.6 29.8 26.2 29
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
123.6B USD 12 -252.2 26.8 28.2
US
Gilead Sciences Inc
NASDAQ:GILD
104.5B USD 3.8 99.3 9.4 12
US
Epizyme Inc
F:EPE
94.1B EUR 1 981.8 -505.7 -550.7 -536
AU
CSL Ltd
ASX:CSL
142.3B AUD 6.5 36.7 22.4 28
US
Seagen Inc
F:SGT
39.3B EUR 19.1 -58.5 -63 -56.9
US
Palatin Technologies Inc
LSE:0KF3
38.5B USD 6 513.5 -1 169.6 -1 185.3 -1 173.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
35.4B USD 15.1 -485.3 213.7 328.9
P/E Multiple
Earnings Growth
NO
L
Lytix Biopharma AS
OSE:LYTIX
Average P/E: 57.6
Negative Multiple: -4.3
N/A
US
Abbvie Inc
NYSE:ABBV
64.6
406%
US
Amgen Inc
NASDAQ:AMGN
57.7
74%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
29.8
56%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -252.2
38%
US
Gilead Sciences Inc
NASDAQ:GILD
99.3
71%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -505.7 N/A
AU
CSL Ltd
ASX:CSL
36.7
64%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.5 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 169.6 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -485.3 N/A
EV/EBITDA Multiple
EBITDA Growth
NO
L
Lytix Biopharma AS
OSE:LYTIX
Average EV/EBITDA: 47.8
Negative Multiple: -3.4
N/A
US
Abbvie Inc
NYSE:ABBV
15.8
28%
US
Amgen Inc
NASDAQ:AMGN
20.2
57%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
26.2
47%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.8
39%
US
Gilead Sciences Inc
NASDAQ:GILD
9.4
10%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -550.7 N/A
AU
CSL Ltd
ASX:CSL
22.4
45%
US
S
Seagen Inc
F:SGT
Negative Multiple: -63 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 185.3 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
213.7
N/A
EV/EBIT Multiple
EBIT Growth
NO
L
Lytix Biopharma AS
OSE:LYTIX
Average EV/EBIT: 69.5
Negative Multiple: -3.4
N/A
US
Abbvie Inc
NYSE:ABBV
24.1
86%
US
Amgen Inc
NASDAQ:AMGN
36.6
95%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
29
49%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.2
38%
US
Gilead Sciences Inc
NASDAQ:GILD
12
26%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -536 N/A
AU
CSL Ltd
ASX:CSL
28
59%
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.9 N/A
US
P
Palatin Technologies Inc
LSE:0KF3
Negative Multiple: -1 173.1 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
328.9
N/A

See Also

Discover More
Back to Top